{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,18]],"date-time":"2026-07-18T03:11:18Z","timestamp":1784344278067,"version":"3.55.0"},"reference-count":93,"publisher":"BMJ","issue":"2","license":[{"start":{"date-parts":[[2020,10,11]],"date-time":"2020-10-11T00:00:00Z","timestamp":1602374400000},"content-version":"unspecified","delay-in-days":10,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100010949","name":"Copenhagen Trial Unit, Centre for Clinical Intervention Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100010949","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["Open Heart"],"accepted":{"date-parts":[[2020,8,19]]},"published-print":{"date-parts":[[2020,10]]},"abstract":"<jats:sec>\n                  <jats:title>Objective<\/jats:title>\n                  <jats:p>To determine the impact of ivabradine on outcomes important to patients with angina pectoris caused by coronary artery disease.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>We conducted a systematic review. We included randomised clinical trials comparing ivabradine versus placebo or no intervention for patients with angina pectoris due to coronary artery disease published prior to June 2020. We used Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines, Cochrane methodology, Trial Sequential Analysis, Grading of Recommendations Assessment, Development, and Evaluation, and our eight-step procedure. Primary outcomes were all-cause mortality, serious adverse events and quality of life.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>We included 47 randomised clinical trials enrolling 35\u2009797 participants. All trials and outcomes were at high risk of bias. Ivabradine compared with control did not have effects when assessing all-cause mortality (risk ratio [RR] 1.04; 95%\u2009CI 0.96 to 1.13), quality of life (standardised mean differences \u22120.05; 95%\u2009CI \u22120.11 to 0.01), cardiovascular mortality (RR 1.07; 95%\u2009CI 0.97 to 1.18) and myocardial infarction (RR 1.03; 95%\u2009CI 0.91 to 1.16). Ivabradine seemed to increase the risk of serious adverse events after removal of outliers (RR 1.07; 95%\u2009CI 1.03 to 1.11) as well as the following adverse events classified as serious: bradycardia, prolonged QT interval, photopsia, atrial fibrillation and hypertension. Ivabradine also increased the risk of non-serious adverse events (RR 1.13; 95% CI 1.11 to 1.16). Ivabradine might have a statistically significant effect when assessing angina frequency (mean difference (MD) 2.06; 95%\u2009CI 0.82 to 3.30) and stability (MD 1.48; 95%\u2009CI 0.07 to 2.89), but the effect sizes seemed minimal and possibly without any relevance to patients, and we identified several methodological limitations, questioning the validity of these results.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>Our findings do not support that ivabradine offers significant benefits on patient important outcomes, but rather seems to increase the risk of serious adverse events such as atrial fibrillation and non-serious adverse events. Based on current evidence, guidelines need reassessment and the use of ivabradine for angina pectoris should be reconsidered.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>PROSPERO registration number<\/jats:title>\n                  <jats:p>CRD42018112082.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1136\/openhrt-2020-001288","type":"journal-article","created":{"date-parts":[[2020,10,12]],"date-time":"2020-10-12T17:06:36Z","timestamp":1602522396000},"page":"e001288","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":8,"title":["Effects of adding ivabradine to usual care in patients with angina pectoris: a systematic review of randomised clinical trials with meta-analysis and Trial Sequential Analysis"],"prefix":"10.1136","volume":"7","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9037-7295","authenticated-orcid":false,"given":"Mathias","family":"Maagaard","sequence":"first","affiliation":[{"name":"Copenhagen Trial Unit, Centre for Clinical Intervention Research, Copenhagen University Hospital, Copenhagen, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1108-9533","authenticated-orcid":false,"given":"Emil Eik","family":"Nielsen","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Holb\u00e6k Hospital, Holb\u00e6k, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naqash Javaid","family":"Sethi","sequence":"additional","affiliation":[{"name":"Copenhagen Trial Unit, Centre for Clinical Intervention Research, Copenhagen University Hospital, Copenhagen, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liang","family":"Ning","sequence":"additional","affiliation":[{"name":"Institute of Basic Research in Clinical Medicine, China Academy of Chinese Medical Sciences Guanganmen Hospital, Xicheng District, China"},{"name":"Centre for Evidence-Based Chinese Medicine, Beijing University of Chinese Medicine, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Si-hong","family":"Yang","sequence":"additional","affiliation":[{"name":"Centre for Evidence-Based Chinese Medicine, Beijing University of Chinese Medicine, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Gluud","sequence":"additional","affiliation":[{"name":"The Cochrane Hepato-Biliary Group, Copenhagen Trial Unit, Centre for Clinical Intervention Research, Copenhagen University Hospital, Copenhagen, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janus Christian","family":"Jakobsen","sequence":"additional","affiliation":[{"name":"Copenhagen Trial Unit, Centre for Clinical Intervention Research, Copenhagen University Hospital, Copenhagen, Denmark"},{"name":"Department of Regional Health Research, The Faculty of Health Sciences, University of Southern Denmark, Odense, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2020,10,12]]},"reference":[{"key":"2025081710472526000_7.2.e001288.1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(14)61682-2"},{"key":"2025081710472526000_7.2.e001288.2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2017.04.052"},{"key":"2025081710472526000_7.2.e001288.3","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/eht296"},{"key":"2025081710472526000_7.2.e001288.4","doi-asserted-by":"publisher","DOI":"10.1177\/1060028016631571"},{"key":"2025081710472526000_7.2.e001288.5","doi-asserted-by":"publisher","DOI":"10.1111\/j.1742-1241.2006.00817.x"},{"key":"2025081710472526000_7.2.e001288.6","doi-asserted-by":"publisher","DOI":"10.1159\/000108387"},{"key":"2025081710472526000_7.2.e001288.7","first-page":"810","article-title":"Ivabradine (Corlanor) for heart failure: the first selective and specific I F inhibitor","volume":"40","author":"Tse","year":"2015","journal-title":"Pharm Ther"},{"key":"2025081710472526000_7.2.e001288.8","doi-asserted-by":"publisher","DOI":"10.1186\/s12874-017-0315-7"},{"key":"2025081710472526000_7.2.e001288.9","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2288-10-90"},{"key":"2025081710472526000_7.2.e001288.10","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2288-14-120"},{"key":"2025081710472526000_7.2.e001288.11","doi-asserted-by":"publisher","DOI":"10.1002\/sim.1186"},{"key":"2025081710472526000_7.2.e001288.12","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.b2535"},{"key":"2025081710472526000_7.2.e001288.13","doi-asserted-by":"crossref","unstructured":"Maagaard M , Nielsen EE , Gluud C , et al . Ivabradine for coronary artery disease and\/or heart failure: a protocol for a systematic review of randomised clinical trials with meta-analysis and trial sequential analysis. PROSPERO 2018 CRD42018112082. Available: http:\/\/www.crd.york.ac.uk\/PROSPERO\/display_record.php?ID=CRD42018112082","DOI":"10.1186\/s13643-019-0957-0"},{"key":"2025081710472526000_7.2.e001288.14","doi-asserted-by":"crossref","DOI":"10.1186\/s13643-019-0957-0","article-title":"Ivabradine for coronary artery disease and\/or heart failure-a protocol for a systematic review of randomised clinical trials with meta-analysis and trial sequential analysis","volume":"8","author":"Maagaard","year":"2019","journal-title":"Syst Rev"},{"key":"2025081710472526000_7.2.e001288.15","unstructured":"Higgins JP , Green S . Cochrane Handbook for systematic reviews of interventions, 2011. Available: www.cochrane-handbook.org"},{"key":"2025081710472526000_7.2.e001288.16","unstructured":"The Cochrane Collaboration . Review Manager (RevMan) [program]. 5.3 version. Copenhagen: The Nordic Cochrane Centre, 2014. https:\/\/training.cochrane.org\/online-learning\/core-software-cochrane-reviews\/revman\/revman-5-download"},{"key":"2025081710472526000_7.2.e001288.17","doi-asserted-by":"publisher","DOI":"10.1093\/ije\/dyn179"},{"key":"2025081710472526000_7.2.e001288.18","unstructured":"Sch\u00fcnemann H , Bro\u017cek J , Guyatt G , et al . GRADE Handbook for grading quality of evidence and strength of recommendations. The GRADE Working Group, 2013. https:\/\/gdt.gradepro.org\/app\/handbook\/handbook.html"},{"key":"2025081710472526000_7.2.e001288.19","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.39489.470347.AD"},{"key":"2025081710472526000_7.2.e001288.20","unstructured":"Servier . ClinicalTrial Servier, 2019. Available: https:\/\/clinicaltrials.servier.com\/ [Accessed 08 Dec 2019]."},{"key":"2025081710472526000_7.2.e001288.21","unstructured":"Servier . Evaluation versus placebo of the effects on heart rate, haemodynamic parameters, safety and tolerability of 5 mg bolus of ivabradine followed by 8-hour infusion of 5mg of ivabradine, given to patients undergoing a percutaneous coronary intervention following a myocardial infarction with ST segment elevation (STEMI). A pilot, blind, randomised, placebo-controlled, international multicentre trial. Including the ancillary MRI sub-study. CL2-16257-060, 2009. Available: https:\/\/clinicaltrials.servier.com\/find-clinical-trials\/"},{"key":"2025081710472526000_7.2.e001288.22","unstructured":"Servier . Evaluation of the anti-anginal efficacy and safety of ivabradine used in combination with an anti-anginal monotherapy in patients with stable effort angina pectoris. A 6-week, randomised, double-blind controlled, parallel-group, international, multicentre study. CL3-16257-064, 2010. Available: https:\/\/clinicaltrials.servier.com\/find-clinical-trials\/"},{"key":"2025081710472526000_7.2.e001288.23","unstructured":"Servier . Evaluation of the anti-anginal efficacy and safety of oral administration of ivabradine compared to placebo on top of a background therapy with a calcium antagonist (amlodipine or nifedipine) in patients with stable angina pectoris. A 6-week randomised double-blind parallel-group international multicentre study. CL3-16257-068, 2012. Available: https:\/\/clinicaltrials.servier.com\/find-clinical-trials\/"},{"key":"2025081710472526000_7.2.e001288.24","unstructured":"Servier . Effects of oral chronic administration of ivabradine (7.5 mg b.i.d.) in comparison to placebo (b.i.d.) on top of beta-blockers, on central aortic blood pressure. Randomised, cross-over, double-blind, multicentre, study over 10 weeks in patients with stable coronary artery disease and a resting heart rate equal or superior to 70 bpm, already treated with beta-blockers. CL2-16257-096, 2014. Available: https:\/\/clinicaltrials.servier.com\/find-clinical-trials\/"},{"key":"2025081710472526000_7.2.e001288.25","unstructured":"Servier . Long-term (3 years) ophthalmic safety and cardiac efficacy and safety of ivabradine administered orally at the therapeutic doses (2.5\/5\/7.5 mg b.i.d.) on top of anti-anginal background therapy, to patients with chronic stable angina pectoris. An international, double-blind placebo controlled study. CL3-16257-067, 2015. Available: https:\/\/clinicaltrials.servier.com\/find-clinical-trials\/"},{"key":"2025081710472526000_7.2.e001288.26","first-page":"1441","article-title":"A clinical study evaluating the effect of ivabradine on non ST-segment elevation acute coronary syndromes","volume":"7","author":"Adel","year":"2016","journal-title":"Int J Pharmaceut Sci Res"},{"key":"2025081710472526000_7.2.e001288.27","first-page":"22","article-title":"[The efficacy and safety of the combination of \u03b2-blocker bisoprolol and if inhibitor I(f) ivabradine in patients with stable angina and chronic obstructive pulmonary disease]","volume":"50","author":"Ageev","year":"2010","journal-title":"Kardiologiia"},{"key":"2025081710472526000_7.2.e001288.28","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.0000048143.25023.87"},{"key":"2025081710472526000_7.2.e001288.29","article-title":"Ivabradine improves short-term outcomes after primary percutaneous coronary intervention in patients presenting with acute ST-segment elevation myocardial infarction","volume":"32","author":"Cay","year":"2011","journal-title":"Eur Heart J"},{"key":"2025081710472526000_7.2.e001288.30","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.1161\/HYPERTENSIONAHA.115.06091","article-title":"Impact of ivabradine on central aortic blood pressure and myocardial perfusion in patients with stable coronary artery disease","volume":"66","author":"Dillinger","year":"2015","journal-title":"Hypertension"},{"key":"2025081710472526000_7.2.e001288.31","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijcard.2012.04.076"},{"key":"2025081710472526000_7.2.e001288.32","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1406430"},{"key":"2025081710472526000_7.2.e001288.33","first-page":"1854","article-title":"Clinical observation of ivabradine combined with amlodipine in treatment of chronic stable angina pectoris","volume":"32","author":"Gao","year":"2017","journal-title":"Drug Clin"},{"key":"2025081710472526000_7.2.e001288.34","doi-asserted-by":"publisher","DOI":"10.1136\/heartjnl-2013-304880"},{"key":"2025081710472526000_7.2.e001288.35","first-page":"475","article-title":"Clinical observation of effect of ivabradine in the treatment of patients with chronic obstructive pulmonary disease complicated with angina pectoris","volume":"21","author":"Hao","year":"2016","journal-title":"Chin J Cardiovasc Med"},{"key":"2025081710472526000_7.2.e001288.36","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1097\/HJH.0000000000001984","article-title":"Effects of heart rate reduction with ivabradine on vascular stiffness and endothelial function in chronic stable coronary artery disease","volume":"37","author":"Hohneck","year":"2019","journal-title":"J Hypertens"},{"key":"2025081710472526000_7.2.e001288.37","first-page":"545","article-title":"The effect of ivabradine on the leve ls of cystatin C in elderly patients with chronic heart failure","volume":"16","author":"Huang","year":"2017","journal-title":"Chin J Difficult Complex cases"},{"key":"2025081710472526000_7.2.e001288.38","first-page":"177","article-title":"Analysis of the effect of ivabradine combined with bisoprolol on coronary heart disease after PCI","volume":"30","author":"Huang","year":"2018","journal-title":"Strait Pharmaceut J"},{"key":"2025081710472526000_7.2.e001288.39","doi-asserted-by":"crossref","DOI":"10.1097\/01.hjh.0000467430.64806.58","article-title":"The effect of ivabradine on silent ambulatory myocardial ischemia","volume":"33","author":"Kadro","year":"2015","journal-title":"J Hypertension"},{"key":"2025081710472526000_7.2.e001288.40","article-title":"Effect of heart rate reduction on peripheral and coronary endothelial function in patients with microvascular angina","volume":"12","author":"Lamendola","year":"2011","journal-title":"Giornale Italiano di Cardiologia"},{"key":"2025081710472526000_7.2.e001288.41","article-title":"Heart rate reduction by ivabradine for improvement of endhotelial function in patients with coronary artery disease: the randomized open-label RIVENDEL study","volume":"36","author":"Mangiacapra","year":"2015","journal-title":"Eur Heart J"},{"key":"2025081710472526000_7.2.e001288.42","first-page":"127","article-title":"Pretreatment with ivabradine reduces periprocedural myocardial injury and infarction in stable ischemic patients undergoing coronary intervention","volume":"35","author":"Naji","year":"2014","journal-title":"Eur Heart J"},{"key":"2025081710472526000_7.2.e001288.43","doi-asserted-by":"crossref","first-page":"54","DOI":"10.18565\/cardio.2015.12.54-62","article-title":"[Clinical efficacy and safety of early administration of ivabradine in patients with acute coronary syndrome]","volume":"55","author":"Shavarov","year":"2015","journal-title":"Kardiologiia"},{"key":"2025081710472526000_7.2.e001288.44","doi-asserted-by":"publisher","DOI":"10.1177\/2048872613489305"},{"key":"2025081710472526000_7.2.e001288.45","article-title":"Comparison of the efficacy and tolerability of ivabradine vs ranolazine vs standard medical therapy in patients of chronic stable angina pectoris despite coronary percutaneous revascularization","volume":"35","author":"Taccheri","year":"2014","journal-title":"Eur Heart J"},{"key":"2025081710472526000_7.2.e001288.46","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehn571"},{"key":"2025081710472526000_7.2.e001288.47","doi-asserted-by":"crossref","unstructured":"Vasyuk YA , Shkolnik E , Lebedev EV . Ivabradine in the treatment of stable angina early after myocardial infarction. Eur J Heart Failure 2009;8.doi:10.1093\/eurheartj\/suv056","DOI":"10.1093\/eurheartj\/suv056"},{"key":"2025081710472526000_7.2.e001288.48","doi-asserted-by":"crossref","DOI":"10.1093\/eurheartj\/eht309.P4002","article-title":"Effectiveness of combination therapy using nebivolol and ivabradine in patients with essential hypertension and stable effort angina","volume":"34","author":"Vatinian","year":"2013","journal-title":"Eur Heart J"},{"key":"2025081710472526000_7.2.e001288.49","first-page":"672","article-title":"Efficacy of addition of ivabradine to bisoprolol in patients with essential hypertension, coronary artery disease and reduced left ventricular systolic function","volume":"36","author":"Vatinian","year":"2015","journal-title":"Eur Heart J"},{"key":"2025081710472526000_7.2.e001288.50","article-title":"Effects of ranolazine and ivabradine on exercise stress test and on coronary and peripheral vascular function in patients with refractory microvascular angina","volume":"33","author":"Villano","year":"2012","journal-title":"Eur Heart J"},{"key":"2025081710472526000_7.2.e001288.51","first-page":"53","article-title":"Clinical efficacy evaluation of ivabradine in treatment of patients with stable angina pectoris complicated with chronic obstructive pulmonary disease","volume":"37","author":"Wang","year":"2018","journal-title":"Chin J New Drugs Clinical Rem"},{"key":"2025081710472526000_7.2.e001288.52","first-page":"58","article-title":"Effect of ivabradine tablets on left ventricular function in patients with coronary heart disease and angina pectoris","volume":"27","author":"Zhang","year":"2018","journal-title":"China Pharmaceut"},{"key":"2025081710472526000_7.2.e001288.53","first-page":"52","article-title":"Ivabradine hydrochloride on the Ef\ufb01cacy and safety of chronic stable angina pectoris","volume":"17","author":"Zhao","year":"2017","journal-title":"World Latest Med Inform"},{"key":"2025081710472526000_7.2.e001288.54","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(08)61170-8"},{"key":"2025081710472526000_7.2.e001288.55","unstructured":"Tagliamonte E , Alfano D , Astarita R , et al . Combined effect of ivabradine on coronary flow reserve and left ventricular contractile reserve in patients with coronary microvascular disease. Eur Heart J Cardiovasc Imag 2019;20."},{"key":"2025081710472526000_7.2.e001288.56","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1007\/s40261-016-0424-9","article-title":"Ivabradine in patients with ST-elevation myocardial infarction complicated by cardiogenic shock: a preliminary randomized prospective study","volume":"36","author":"Barill\u00e0","year":"2016","journal-title":"Clin Drug Investig"},{"key":"2025081710472526000_7.2.e001288.57","first-page":"1428","article-title":"Efficacy of ivabradine in treating acute myocardial infarction patients with heart failure","volume":"44","author":"Hu","year":"2018","journal-title":"Jiangsu Med"},{"key":"2025081710472526000_7.2.e001288.58","first-page":"41","article-title":"Intravenous ivabradine in low cardiac output syndrome after cardiac surgery treated by dobutamine: a phase II trial","volume":"10","author":"Nguyen","year":"2018","journal-title":"Arch Cardiovasc Dis Suppl"},{"key":"2025081710472526000_7.2.e001288.59","doi-asserted-by":"crossref","first-page":"481","DOI":"10.2174\/1570161114666160505143003","article-title":"Impact of ivabradine on health-related quality of life of patients with ischaemic chronic heart failure","volume":"14","author":"Sallam","year":"2016","journal-title":"Curr Vasc Pharmacol"},{"key":"2025081710472526000_7.2.e001288.60","first-page":"40","article-title":"[Clinical efficacy of ivabradin and nebivolol addition in combined treatment of ischemic heart disease patients with left ventricular dysfunction]","volume":"80","author":"Tatarchenko","year":"2008","journal-title":"Ter Arkh"},{"key":"2025081710472526000_7.2.e001288.61","first-page":"256","article-title":"Clinical effect of ivabradine on coronary heart disease combined with chronic obstructive pulmonary disease","volume":"48","author":"Zhang","year":"2019","journal-title":"Shaanxi Med J"},{"key":"2025081710472526000_7.2.e001288.62","first-page":"36","article-title":"Effect of ivabradine combined with bisoprolol on cardiac rehabilitation in patients with coronary heart disease after percutaneous coronary intervention","volume":"9","author":"Chen","year":"2019","journal-title":"China Med Pharm"},{"key":"2025081710472526000_7.2.e001288.63","first-page":"70","article-title":"The improvement of ventricular remodeling in patients with coronary heart disease and heart failure by ivabradine","volume":"25","author":"He","year":"2019","journal-title":"Contemp Med"},{"key":"2025081710472526000_7.2.e001288.64","first-page":"111","article-title":"Effect of ivabradine and nicorandil on cardiac functions and exercise endurance in patients with coronary heart disease after PCI","volume":"16","author":"Wang","year":"2019","journal-title":"Chin J Rational Drug Use"},{"key":"2025081710472526000_7.2.e001288.65","first-page":"22","article-title":"Effect of ivabradine on patients with coronary atherosclerotic heart disease and angina pectoris and influence on left ventricular function","volume":"12","author":"Zhou","year":"2019","journal-title":"Chin J Clin Rational Drug Use"},{"key":"2025081710472526000_7.2.e001288.66","first-page":"146","article-title":"Effect of ivabradine on patients with diabetes mellitus with coronary heart disease","volume":"18","author":"Di","year":"2020","journal-title":"Chin J Cardiovasc Res"},{"key":"2025081710472526000_7.2.e001288.67","first-page":"11","article-title":"Effect of ivabradine combined with metoprolol on cardiac function and carotid intima-media thickness of patients with coronary heart disease complicated with heart failure","volume":"32","author":"Zhang","year":"2020","journal-title":"Med J Chin People Health"},{"key":"2025081710472526000_7.2.e001288.68","first-page":"52","article-title":"Selective I-f-channel inhibitor ivabradine in the treatment of sinus tachycardia in coronary heart disease patients with acute heart failure and inferior myocardial infarction","volume":"9","author":"Sayganov","year":"2010","journal-title":"Cardiovasc Ther Prevent"},{"key":"2025081710472526000_7.2.e001288.69","first-page":"151","article-title":"The effect of ivabradine combined with bisoprolol on rehabilitation of patients with coronar y heart disease after p ercutaneous coronar y intervention","volume":"37","author":"Huang","year":"2017","journal-title":"Chin Hosp Pharm J"},{"key":"2025081710472526000_7.2.e001288.70","doi-asserted-by":"publisher","DOI":"10.1016\/j.ahj.2006.01.013"},{"key":"2025081710472526000_7.2.e001288.71","unstructured":"Servier . The beautiful study: effects of ivabradine in patients with stable coronary artery disease and left ventricular systolic dysfunction. ClinicalTrials.gov: Servier, 2005."},{"key":"2025081710472526000_7.2.e001288.72","doi-asserted-by":"publisher","DOI":"10.1016\/j.ahj.2013.06.024"},{"key":"2025081710472526000_7.2.e001288.73","unstructured":"Servier . Effects of ivabradine in patients with stable coronary artery disease without clinical heart failure (SIGNIFY). ClinicalTrials.gov: Servier, 2015."},{"key":"2025081710472526000_7.2.e001288.74","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCOUTCOMES.115.002091"},{"key":"2025081710472526000_7.2.e001288.75","doi-asserted-by":"publisher","DOI":"10.1093\/ije\/dyu115"},{"key":"2025081710472526000_7.2.e001288.76","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.e1119"},{"key":"2025081710472526000_7.2.e001288.77","doi-asserted-by":"publisher","DOI":"10.1503\/cmaj.120744"},{"key":"2025081710472526000_7.2.e001288.78","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-157-6-201209180-00537"},{"key":"2025081710472526000_7.2.e001288.79","doi-asserted-by":"publisher","DOI":"10.1093\/aje\/kwx344"},{"key":"2025081710472526000_7.2.e001288.80","doi-asserted-by":"crossref","unstructured":"Lundh A , Lexchin J , Mintzes B , et al . Industry sponsorship and research outcome. Cochrane Database Syst Rev 2017;29.doi:10.1002\/14651858.MR000033.pub3","DOI":"10.1002\/14651858.MR000033.pub3"},{"key":"2025081710472526000_7.2.e001288.81","unstructured":"Thorlund K , Engstr\u00f8m J , Wetterslev J , et al . User manual for Trial Sequential Analysis (TSA): Copenhagen Trial Unit, 2017. Available: http:\/\/www.ctu.dk\/tsa\/files\/tsa_manual.pdf [Accessed 10 Dec 2019]."},{"key":"2025081710472526000_7.2.e001288.82","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehz425"},{"key":"2025081710472526000_7.2.e001288.83","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000003245","article-title":"Effectiveness of ivabradine in treating stable angina pectoris","volume":"95","author":"Ye","year":"2016","journal-title":"Medicine"},{"key":"2025081710472526000_7.2.e001288.84","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1002\/clc.22578","article-title":"The risk of atrial fibrillation with ivabradine treatment: a meta-analysis with trial sequential analysis of more than 40000 patients","volume":"39","author":"Tanbo\u011fa","year":"2016","journal-title":"Clin Cardiol"},{"key":"2025081710472526000_7.2.e001288.85","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000008067","article-title":"Ivabradine has a neutral effect on mortality in randomized controlled trials","volume":"96","author":"Kang","year":"2017","journal-title":"Medicine"},{"key":"2025081710472526000_7.2.e001288.86","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/j.clinthera.2015.12.018","article-title":"Meta-analysis of ivabradine in patients with stable coronary artery disease with and without left ventricular dysfunction","volume":"38","author":"Cammarano","year":"2016","journal-title":"Clin Ther"},{"key":"2025081710472526000_7.2.e001288.87","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.39465.451748.AD"},{"key":"2025081710472526000_7.2.e001288.88","doi-asserted-by":"publisher","DOI":"10.1001\/jama.1995.03520290060030"},{"key":"2025081710472526000_7.2.e001288.89","doi-asserted-by":"crossref","DOI":"10.3310\/hta16350","article-title":"Influence of reported study design characteristics on intervention effect estimates from randomised controlled trials: combined analysis of meta-epidemiological studies","volume":"16","author":"Savovi\u0107","year":"2012","journal-title":"Health Technol Assess"},{"key":"2025081710472526000_7.2.e001288.90","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(98)01085-X"},{"key":"2025081710472526000_7.2.e001288.91","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-135-11-200112040-00010"},{"key":"2025081710472526000_7.2.e001288.92","doi-asserted-by":"publisher","DOI":"10.1093\/aje\/kwj069"},{"key":"2025081710472526000_7.2.e001288.93","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2016.03.610"}],"container-title":["Open Heart"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/openhrt-2020-001288","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,17]],"date-time":"2025-08-17T17:47:41Z","timestamp":1755452861000},"score":1,"resource":{"primary":{"URL":"https:\/\/openheart.bmj.com\/lookup\/doi\/10.1136\/openhrt-2020-001288"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10]]},"references-count":93,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2020,10,12]]},"published-print":{"date-parts":[[2020,10]]}},"alternative-id":["10.1136\/openhrt-2020-001288"],"URL":"https:\/\/doi.org\/10.1136\/openhrt-2020-001288","relation":{},"ISSN":["2053-3624"],"issn-type":[{"value":"2053-3624","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,10]]}}}